

# Not all TAVR valves are made alike. Your valve choice matters.


## Edwards SAPIEN 3 Transcatheter Aortic Heart Valves

If you have severe aortic stenosis and are experiencing symptoms, you now have even more choices when it comes to which transcatheter aortic valve replacement (TAVR) valve you receive.

By choosing one of the Edwards transcatheter heart valves, you are getting one of the most widely used TAVR valves around the world, having been implanted in over 763,000 patients around the world.\*



SAPIEN 3 Ultra valve



SAPIEN 3 Ultra RESILIA valve

The SAPIEN 3 Ultra RESILIA valve is the latest valve approved in the SAPIEN 3 TAVR family of valves.

## The SAPIEN 3 TAVR valves are specifically designed with you in mind, giving you better clinical outcomes than open heart surgery.†



### Designed Like Your Heart

- The valves are designed to work like your native valve and begin working immediately once they are implanted.



### Designed to Last

- The frame of the valves is made from cobalt chromium to help with strength and durability.
- TAVR with the SAPIEN 3 family of valves, has similar durability to that of the leading surgical valves at 5 years.<sup>12‡§</sup>
- An outer sealing skirt surrounds the bottom of the valve, to help reduce any possible leakage around the valve.



### Designed for Your Unique Needs

- SAPIEN 3 TAVR valves come in four unique sizes to provide a better fit for each individual patient.



### Designed for Your Future

- The SAPIEN 3 TAVR valves are designed purposely with a specific low frame height to facilitate future procedures, if needed.<sup>3¶</sup>
- The SAPIEN 3 Ultra RESILIA valve is a bovine (cow) heart tissue that has been treated with a special Edwards technology to block calcium build-up on the valve, potentially allowing the valve to last longer.<sup>1‡</sup>
- Up to 75% of patients who get TAVR also have coronary artery disease.<sup>4</sup> By getting one of the SAPIEN 3 TAVR valves, your physician may have better access to your coronaries in the future, should you need another procedure, due to its unique shape and low frame height design.

\*Currently, does not include the SAPIEN 3 Ultra RESILIA valve.

†The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.

‡RESILIA tissue has not been studied for long-term results in patients.


§Propensity matched analysis of intermediate risk patients using VARC3 definitions of SVD and SVD related BVF at 5 years.

¶Indication for aortic THV-in-THV with demonstrated future coronary access (68/68 patients).



Edwards

# The SAPIEN 3 Ultra RESILIA valve gives patients even more reason to ask for a specific TAVR valve



## The SAPIEN 3 Ultra RESILIA valve is the only TAVR valve with RESILIA tissue<sup>1†</sup>

- Both the SAPIEN 3 Ultra RESILIA valve and the leading surgical valves use RESILIA tissue, known to block calcium build-up on the tissue, which could potentially allow the valve to last longer.<sup>1‡</sup>
- Before today, the RESILIA tissue was only approved to be used on surgical heart valves<sup>‡</sup>

## What are you waiting for? Understand why your choice of TAVR valve matters

➤ **Now is the time to ask for one of the SAPIEN 3 TAVR valves when getting TAVR. Learn why at [TAVRbyEdwards.com](https://TAVRbyEdwards.com).**

<sup>‡</sup>Currently, does not include the SAPIEN 3 Ultra RESILIA valve.

<sup>†</sup>The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.

<sup>‡</sup>RESILIA tissue has not been studied for long-term results in patients.

<sup>§</sup>Propensity matched analysis of intermediate risk patients using VARC3 definitions of SVD and SVD related BVF at 5 years.

<sup>¶</sup>Indication for aortic THV-in-THV with demonstrated future coronary access (68/68 patients).

### References

1. Flameng et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. *J Thorac Cardiovasc Surg.* 2015;149:340–5.
2. Pibarot P, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprosthesis in PARTNER-2 trial. *J Am Coll Cardiol.* 2020;76:1830-1843.
3. Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. *Circ Cardiovasc Interv.* 2020;13(7):e008972. doi:10.1161/CIRCINTERVENTIONS.120.008972.
4. Yudi MB, et al. Coronary Angiography and Percutaneous Coronary Intervention after Transcatheter Aortic Valve Replacement. *JACC* 2018: 1360–78.

### See accompanying Important Risk Information.

**CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.**

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, RESILIA, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, and TAVRbyEdwards.com are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--US-7342 v1.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • [edwards.com](https://edwards.com)

